Sustainable Strategies for Optimally Integrating FcRn Inhibitors into Individualized Treatment Paradigms for Generalized Myasthenia Gravis - CME - Guideline Central

CME

Title
Sustainable Strategies for Optimally Integrating FcRn Inhibitors into Individualized Treatment Paradigms for Generalized Myasthenia Gravis
Link
Description
No two patients with generalized myasthenia gravis (gMG) are the same and individualizing treatment is vital. Recent data reveal that patients with gMG treated with older therapies often express negative sentiment towards MG symptoms, particularly fear, and desire treatments that offer symptom control, convenience, and flexibility, highlighting the need for improved therapeutic decision-making. The advent of novel neonatal Fc receptor (FcRn) inhibitors has shifted the treatment paradigm to address these unmet needs, increasing the potential for patients to achieve minimal manifestation status and reducing the burden of disease. To help you adeptly navigate the complexities of treatment, immerse yourself in this interactive “choose your path” decision tree and supporting practice compendium with expert perspectives to assist with the application of the latest evidence to individualize therapy for this “snowflake” disease.
Target Audience
This activity is intended for neurologists, neuromuscular specialists, and advanced practice providers in the specialty setting.
Learning Objectives
  • Discuss the clinical burden often associated with generalized myasthenia gravis (gMG)
  • Appraise the latest clinical trial data supporting the efficacy and safety of new and emerging neonatal Fc receptor (FcRn) inhibitors in patients with gMG
  • Integrate FcRn inhibitors into individualized treatment plans for gMG, balancing efficacy, safety, dosing frequency, and patient preferences
Estimated Duration
90 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Neurology
Keywords
FcRn Inhibitors, generalized myasthenia gravis (gMG)
Disclosures and Disclaimers
Disclosures: All relevant financial relationships for anyone with the ability to control the content of this educational activity have been mitigated. Disclaimer: Content is current as of the date this activity was released. The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
Accredited Providers
  • Academy for Continued Healthcare Learning (ACHL)
Commercial Support
  • argenx US Inc
Activity Expiration Date
August 29, 2026
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1.5 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.